Evaluation of the Highly Variable Agomelatine Pharmacokinetics in Chinese Healthy Subjects to Support Bioequivalence Study
Open Access
- 20 October 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e109300
Abstract
We aim to obtain the intra-subject coefficient of variability of a highly variable antidepressant agomelatine in humans, and propose an adjusted bioequivalence assessment strategy. A single-dose, randomized crossover design was conducted in four periods (reference administered thrice, placebo administered once) separated by seven days. A validated LC-MS/MS assay was used to measure drug concentrations in serial blood samples. The intra-subject coefficient of variability was calculated using the residual variance of ANOVA analysis, and the results for Cmax and AUC0-t was 78.34% and 43.52%, respectively, in Chinese healthy subjects. The sample size required for standard BE study were 124(192, 340) if the expected deviation between the reference and generic products was set to 0 (5%, 10%). Agomelatine meets the criteria for highly variable drug in Chinese healthy male subjects, and the traditional BE criteria for agomelatine needs to be adjusted to alleviate the resource and ethical burden of using a large numbers of subjects in clinical trials. Our clinical data on the intra-subject variability of agomelatine PK in Chinese healthy population enables to adjust bioequivalence (BE) assessment approach for agomelatine based on the RSABE approaches recommended by regulatory agencies. ChiCTR.org ChiCTR-TTRCC-13003835Keywords
This publication has 15 references indexed in Scilit:
- Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trialsThe British Journal of Psychiatry, 2013
- LC‐MS/MS method for the determination of agomelatine in human plasma and its application to a pharmacokinetic studyBiomedical Chromatography, 2013
- The Efficacy of Agomelatine in Elderly Patients With Recurrent Major Depressive DisorderThe Journal of Clinical Psychiatry, 2013
- Validated LC–MS/MS method for quantification of agomelatine in human plasma and its application in a pharmacokinetic studyJournal of Mass Spectrometry, 2012
- Evaluation of a Scaling Approach for the Bioequivalence of Highly Variable DrugsThe AAPS Journal, 2008
- Highly Variable Drugs: Observations from Bioequivalence Data Submitted to the FDA for New Generic Drug ApplicationsThe AAPS Journal, 2008
- Comparative Study on the Bioequivalence of Two Formulations of PravastatinArzneimittelforschung, 2006
- The bioequivalence of highly variable drugs and drug productsInt. Journal of Clinical Pharmacology and Therapeutics, 2005
- Bio-International 92, Conference on Bioavailability, Bioequivalence, and Pharmacokinetic StudiesJournal of Pharmaceutical Sciences, 1993
- Sample size determination for the two one-sided tests procedure in bioequivalenceJournal of Pharmacokinetics and Biopharmaceutics, 1992